Inflammation as a driver and vulnerability of KRAS mediated oncogenesis

Seminars in Cell and Developmental Biology

Volumn 58, Issue , 2016, Pages 127-135

  Kitajima, Shunsuke ^a   Thummalapalli, Rohit ^a,b   Barbie, David A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Autophagy; Cytokines; Inflammation; KRAS; NF B; STAT3

Indexed keywords

ACETYLSALICYLIC ACID; CAPECITABINE; CYCLOOXYGENASE 2; JANUS KINASE 1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MOMELOTINIB; NONSTEROID ANTIINFLAMMATORY AGENT; RUXOLITINIB; SELUMETINIB; STAT3 PROTEIN; TRAMETINIB; RAS PROTEIN;

AUTOPHAGY; CARCINOGENESIS; COLITIS; COLORECTAL CANCER; DRUG TARGETING; ENZYME INHIBITION; HUMAN; INFLAMMATION; LUNG ADENOCARCINOMA; NONHUMAN; ONCOGENE K RAS; PANCREAS CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AUTOPHAGY; CARCINOGENESIS; HUMANS; INFLAMMATION; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84991098707     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2016.06.009     Document Type: Review

References (76)

1. [1] Stephen, A.G., Esposito, D., Bagni, R.K., McCormick, F., Dragging ras back in the ring. Cancer Cell 25:3 (2014), 272–281.
2. [2] Golay, H.G., Barbie, D.A., Targeting cytokine networks in KRAS-driven tumorigenesis. Expert Rev. Anticancer Ther. 14:8 (2014), 869–871.
3. [3] Guibert, N., Ilie, M., Long, E., Hofman, V., Bouhlel, L., Brest, P., Mograbi, B., Marquette, C.H., Didier, A., Mazieres, J., Hofman, P., KRAS mutations in lung adenocarcinoma: molecular and epidemiological characteristics, methods for detection, and therapeutic strategy perspectives. Curr. Mol. Med. 15:5 (2015), 418–432.
4. [4] Fritz, J.M., Dwyer-Nield, L.D., Russell, B.M., Malkinson, A.M., The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers. J. Thorac. Oncol. 5:2 (2010), 254–257.
5. [5] Westcott, P.M., Halliwill, K.D., To, M.D., Rashid, M., Rust, A.G., Keane, T.M., Delrosario, R., Jen, K.Y., Gurley, K.E., Kemp, C.J., Fredlund, E., Quigley, D.A., Adams, D.J., Balmain, A., The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517:7535 (2015), 489–492.
6. [6] Stathopoulos, G.T., Sherrill, T.P., Cheng, D.S., Scoggins, R.M., Han, W., Polosukhin, V.V., Connelly, L., Yull, F.E., Fingleton, B., Blackwell, T.S., Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 104:47 (2007), 18514–18519.
7. [7] Meylan, E., Dooley, A.L., Feldser, D.M., Shen, L., Turk, E., Ouyang, C., Jacks, T., Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462:7269 (2009), 104–107.
8. [8] Basseres, D.S., Ebbs, A., Levantini, E., Baldwin, A.S., Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 70:9 (2010), 3537–3546.
9. [9] Basseres, D.S., Ebbs, A., Cogswell, P.C., Baldwin, A.S., IKK is a therapeutic target in KRAS-induced lung cancer with disrupted p53 activity. Genes Cancer 5:1–2 (2014), 41–55.
10. [10] Zhou, J., Qu, Z., Yan, S., Sun, F., Whitsett, J.A., Shapiro, S.D., Xiao, G., Differential roles of STAT3 in the initiation and growth of lung cancer. Oncogene 34:29 (2015), 3804–3814.
11. [11] Grabner, B., Schramek, D., Mueller, K.M., Moll, H.P., Svinka, J., Hoffmann, T., Bauer, E., Blaas, L., Hruschka, N., Zboray, K., Stiedl, P., Nivarthi, H., Bogner, E., Gruber, W., Mohr, T., Zwick, R.H., Kenner, L., Poli, V., Aberger, F., Stoiber, D., Egger, G., Esterbauer, H., Zuber, J., Moriggl, R., Eferl, R., Gyorffy, B., Penninger, J.M., Popper, H., Casanova, E., Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat. Commun., 6, 2015, 6285.
12. [12] Tan, X., Carretero, J., Chen, Z., Zhang, J., Wang, Y., Chen, J., Li, X., Ye, H., Tang, C., Cheng, X., Hou, N., Yang, X., Wong, K.K., Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. PLoS One, 8(11), 2013, e80885.
13. [13] Qu, Z., Sun, F., Zhou, J., Li, L., Shapiro, S.D., Xiao, G., Interleukin-6 prevents the initiation but enhances the progression of lung cancer. Cancer Res. 75:16 (2015), 3209–3215.
14. [14] Koyama, S., Akbay, E.A., Li, Y.Y., Aref, A.R., Skoulidis, F., Herter-Sprie, G.S., Buczkowski, K.A., Liu, Y., Awad, M.M., Denning, W.L., Diao, L., Wang, J., Parra Cuentas, E.R., Wistuba, I.I., Soucheray, M., Thai, T.C., Asahina, H., Kitajima, S., Altabef, A., Cavanaugh, J.D., Rhee, K., Gao, P., Zhang, H., Fecci, P.E., Shimamura, T., Hellmann, M., Heymach, J.V., Hodi, F.S., Freeman, G.J., Barbie, D.A., Dranoff, G., Hammerman, P.S., Wong, K.K., STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment. Cancer Res. 76:5 (2016), 999–1008.
15. [15] Ji, H., Ramsey, M.R., Hayes, D.N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M.C., Shimamura, T., Perera, S.A., Liang, M.C., Cai, D., Naumov, G.N., Bao, L., Contreras, C.M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L.R., Padera, R.F., Bronson, R.T., Lindeman, N.I., Christiani, D.C., Lin, X., Shapiro, G.I., Janne, P.A., Johnson, B.E., Meyerson, M., Kwiatkowski, D.J., Castrillon, D.H., Bardeesy, N., Sharpless, N.E., Wong, K.K., LKB1 modulates lung cancer differentiation and metastasis. Nature 448:7155 (2007), 807–810.
16. [16] Bailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A.M., Gingras, M.C., Miller, D.K., Christ, A.N., Bruxner, T.J., Quinn, M.C., Nourse, C., Murtaugh, L.C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M.J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P.J., Cloonan, N., Kassahn, K.S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L.N., Evers, L., Wu, J., Pinese, M., Cowley, M.J., Jones, M.D., Colvin, E.K., Nagrial, A.M., Humphrey, E.S., Chantrill, L.A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C.J., Pinho, A.V., Giry-Laterriere, M., Rooman, I., Samra, J.S., Kench, J.G., Lovell, J.A., Merrett, N.D., Toon, C.W., Epari, K., Nguyen, N.Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N.B., Graham, J.S., Duthie, F., Oien, K., Hair, J., Grutzmann, R., Maitra, A., Iacobuzio-Donahue, C.A., Wolfgang, C.L., Morgan, R.A., Lawlor, R.T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G.M., Australian Pancreatic Cancer Genome, I., Munzy, D.M., Fisher, W.E., Karim, S.A., Eshleman, J.R., Hruban, R.H., Pilarsky, C., Morton, J.P., Sansom, O.J., Scarpa, A., Musgrove, E.A., Bailey, U.M., Hofmann, O., Sutherland, R.L., Wheeler, D.A., Gill, A.J., Gibbs, R.A., Pearson, J.V., Waddell, N., Biankin, A.V., Grimmond, S.M., Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:7592 (2016), 47–52.
17. [17] Becker, A.E., Hernandez, Y.G., Frucht, H., Lucas, A.L., Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J. Gastroenterol. 20:32 (2014), 11182–11198.
18. [18] LaRusch, J., Whitcomb, D.C., Genetics of pancreatitis. Curr. Opin. Gastroenterol. 27:5 (2011), 467–474.
19. [19] Ostrow, S.L., Simon, E., Prinz, E., Bick, T., Shentzer, T., Nagawkar, S.S., Sabo, E., Ben-Izhak, O., Hershberg, R., Hershkovitz, D., Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection. Sci. Rep., 6, 2016, 21927.
20. [20] Collins, M.A., Bednar, F., Zhang, Y., Brisset, J.C., Galban, S., Galban, C.J., Rakshit, S., Flannagan, K.S., Adsay, N.V., Pasca di Magliano, M., Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 122:2 (2012), 639–653.
21. [21] Daniluk, J., Liu, Y., Deng, D., Chu, J., Huang, H., Gaiser, S., Cruz-Monserrate, Z., Wang, H., Ji, B., Logsdon, C.D., An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J. Clin. Invest. 122:4 (2012), 1519–1528.
22. [22] Zhang, Y., Yan, W., Collins, M.A., Bednar, F., Rakshit, S., Zetter, B.R., Stanger, B.Z., Chung, I., Rhim, A.D., di Magliano, M.P., Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 73:20 (2013), 6359–6374.
23. [23] Maier, H.J., Wagner, M., Schips, T.G., Salem, H.H., Baumann, B., Wirth, T., Requirement of NEMO/IKKgamma for effective expansion of KRAS-induced precancerous lesions in the pancreas. Oncogene 32:21 (2013), 2690–2695.
24. [24] Ling, J., Kang, Y., Zhao, R., Xia, Q., Lee, D.F., Chang, Z., Li, J., Peng, B., Fleming, J.B., Wang, H., Liu, J., Lemischka, I.R., Hung, M.C., Chiao, P.J., KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21:1 (2012), 105–120.
25. [25] Lesina, M., Kurkowski, M.U., Ludes, K., Rose-John, S., Treiber, M., Kloppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., Schmid, R.M., Algul, H., Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19:4 (2011), 456–469.
26. [26] Fukuda, A., Wang, S.C., Morris, J.P.t., Folias, A.E., Liou, A., Kim, G.E., Akira, S., Boucher, K.M., Firpo, M.A., Mulvihill, S.J., Hebrok, M., Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19:4 (2011), 441–455.
27. [27] Corcoran, R.B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C.H., Levy, D.E., Settleman, J., Engelman, J.A., Bardeesy, N., STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 71:14 (2011), 5020–5029.
28. [28] Kinzler, K.W., Vogelstein, B., Lessons from hereditary colorectal cancer. Cell 87:2 (1996), 159–170.
29. [29] Nistal, E., Fernandez-Fernandez, N., Vivas, S., Olcoz, J.L., Factors determining colorectal cancer: the role of the intestinal microbiota. Front. Oncol., 5, 2015, 220.
30. [30] Grivennikov, S.I., Inflammation and colorectal cancer: colitis-associated neoplasia. Semin. Immunopathol. 35:2 (2013), 229–244.
31. [31] Brown, J.B., Lee, G., Managlia, E., Grimm, G.R., Dirisina, R., Goretsky, T., Cheresh, P., Blatner, N.R., Khazaie, K., Yang, G.Y., Li, L., Barrett, T.A., Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology 138:2 (2010), 595–605 605.e1-3.
32. [32] Robles, A.I., Traverso, G., Zhang, M., Roberts, N.J., Khan, M.A., Joseph, C., Lauwers, G.Y., Selaru, F.M., Popoli, M., Pittman, M.E., Ke, X., Hruban, R.H., Meltzer, S.J., Kinzler, K.W., Vogelstein, B., Harris, C.C., Papadopoulos, N., Whole-exome sequencing analyses of inflammatory bowel disease-associated colorectal cancers. Gastroenterology 150:4 (2016), 931–943.
33. [33] Vivona, A.A., Shpitz, B., Medline, A., Bruce, W.R., Hay, K., Ward, M.A., Stern, H.S., Gallinger, S., K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis 14:9 (1993), 1777–7181.
34. [34] Maltzman, T., Whittington, J., Driggers, L., Stephens, J., Ahnen, D., AOM-induced mouse colon tumors do not express full-length APC protein. Carcinogenesis 18:12 (1997), 2435–2439.
35. [35] Takahashi, M., Nakatsugi, S., Sugimura, T., Wakabayashi, K., Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 21:6 (2000), 1117–1120.
36. [36] De Robertis, M., Massi, E., Poeta, M.L., Carotti, S., Morini, S., Cecchetelli, L., Signori, E., Fazio, V.M., The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J. Carcinog., 10, 2011, 9.
37. [37] Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., Kagnoff, M.F., Karin, M., IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:3 (2004), 285–296.
38. [38] Rigby, R.J., Simmons, J.G., Greenhalgh, C.J., Alexander, W.S., Lund, P.K., Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 26:33 (2007), 4833–4841.
39. [39] Fukata, M., Chen, A., Vamadevan, A.S., Cohen, J., Breglio, K., Krishnareddy, S., Hsu, D., Xu, R., Harpaz, N., Dannenberg, A.J., Subbaramaiah, K., Cooper, H.S., Itzkowitz, S.H., Abreu, M.T., Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133:6 (2007), 1869–1881.
40. [40] Kimmelman, A.C., The dynamic nature of autophagy in cancer. Genes Dev. 25:19 (2011), 1999–2010.
41. [41] White, E., Mehnert, J.M., Chan, C.S., Autophagy metabolism, and cancer. Clin. Cancer Res. 21:22 (2015), 5037–5046.
42. [42] Yang, A., Rajeshkumar, N.V., Wang, X., Yabuuchi, S., Alexander, B.M., Chu, G.C., Von Hoff, D.D., Maitra, A., Kimmelman, A.C., Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov. 4:8 (2014), 905–913.
43. [43] Mancias, J.D., Wang, X., Gygi, S.P., Harper, J.W., Kimmelman, A.C., Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 509:7498 (2014), 105–109.
44. [44] Duran, A., Linares, J.F., Galvez, A.S., Wikenheiser, K., Flores, J.M., Diaz-Meco, M.T., Moscat, J., The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 13:4 (2008), 343–354.
45. [45] Liu, S., Feng, M., Guan, W., Mitochondrial DNA sensing by STING signaling participates in inflammation, cancer and beyond. Int. J. Cancer, 2016.
46. [46] Mathew, R., Khor, S., Hackett, S.R., Rabinowitz, J.D., Perlman, D.H., White, E., Functional role of autophagy-mediated proteome remodeling in cell survival signaling and innate immunity. Mol. Cell 55:6 (2014), 916–930.
47. [47] Yang, S., Imamura, Y., Jenkins, R., Canadas, I., Kitajima, S., Aref, A.R., Brannon, A.L., Oki, E., Castoreno, A., Zhu, Z., Thai, T.C., Reibel, J., Qian, Z., Ogino, S., Wong, K.K., Baba, H., Kimmelman, A.C., Pasca di Magliano, M., Barbie, D.A., Autophagy inhibition dysregulates TBK1 signaling and promotes pancreatic inflammation. Cancer Immunol. Res. 4:6 (2016), 520–530.
48. [48] Shackelford, D.B., Abt, E., Gerken, L., Vasquez, D.S., Seki, A., Leblanc, M., Wei, L., Fishbein, M.C., Czernin, J., Mischel, P.S., Shaw, R.J., LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23:2 (2013), 143–158.
49. [49] Rao, S., Tortola, L., Perlot, T., Wirnsberger, G., Novatchkova, M., Nitsch, R., Sykacek, P., Frank, L., Schramek, D., Komnenovic, V., Sigl, V., Aumayr, K., Schmauss, G., Fellner, N., Handschuh, S., Glosmann, M., Pasierbek, P., Schlederer, M., Resch, G.P., Ma, Y., Yang, H., Popper, H., Kenner, L., Kroemer, G., Penninger, J.M., A dual role for autophagy in a murine model of lung cancer. Nat. Commun., 5, 2014, 3056.
50. [50] de Lange, K.M., Barrett, J.C., Understanding inflammatory bowel disease via immunogenetics. J. Autoimmun. 64 (2015), 91–100.
51. [51] Tsuboi, K., Nishitani, M., Takakura, A., Imai, Y., Komatsu, M., Kawashima, H., Autophagy protects against colitis by the maintenance of normal gut microflora and secretion of mucus. J. Biol. Chem. 290:33 (2015), 20511–20526.
52. [52] Wlodarska, M., Thaiss, C.A., Nowarski, R., Henao-Mejia, J., Zhang, J.P., Brown, E.M., Frankel, G., Levy, M., Katz, M.N., Philbrick, W.M., Elinav, E., Finlay, B.B., Flavell, R.A., NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 156:5 (2014), 1045–1059.
53. [53] N. Cancer Genome Atlas Research, Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:7511 (2014), 543–550.
54. [54] Skoulidis, F., Byers, L.A., Diao, L., Papadimitrakopoulou, V.A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E.R., Canales, J.R., Zhang, J., Giri, U., Gudikote, J., Cortez, M.A., Yang, C., Fan, Y., Peyton, M., Girard, L., Coombes, K.R., Toniatti, C., Heffernan, T.P., Choi, M., Frampton, G.M., Miller, V., Weinstein, J.N., Herbst, R.S., Wong, K.K., Zhang, J., Sharma, P., Mills, G.B., Hong, W.K., Minna, J.D., Allison, J.P., Futreal, A., Wang, J., Wistuba, I.I., Heymach, J.V., Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5:8 (2015), 860–877.
55. [55] Schabath, M.B., Welsh, E.A., Fulp, W.J., Chen, L., Teer, J.K., Thompson, Z.J., Engel, B.E., Xie, M., Berglund, A.E., Creelan, B.C., Antonia, S.J., Gray, J.E., Eschrich, S.A., Chen, D.T., Cress, W.D., Haura, E.B., Beg, A.A., Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene 35:24 (2015), 3209–3216.
56. [56] Hopewell, E.L., Zhao, W., Fulp, W.J., Bronk, C.C., Lopez, A.S., Massengill, M., Antonia, S., Celis, E., Haura, E.B., Enkemann, S.A., Chen, D.T., Beg, A.A., Lung tumor NF-kappaB signaling promotes T cell-mediated immune surveillance. J. Clin. Invest. 123:6 (2013), 2509–2522.
57. [57] Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., Miller, M.L., Rekhtman, N., Moreira, A.L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E.B., Merghoub, T., Wolchok, J.D., Schumacher, T.N., Chan, T.A., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:6230 (2015), 124–128.
58. [58] McGranahan, N., Furness, A.J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., Watkins, T.B., Shafi, S., Murugaesu, N., Mitter, R., Akarca, A.U., Linares, J., Marafioti, T., Henry, J.Y., Van Allen, E.M., Miao, D., Schilling, B., Schadendorf, D., Garraway, L.A., Makarov, V., Rizvi, N.A., Snyder, A., Hellmann, M.D., Merghoub, T., Wolchok, J.D., Shukla, S.A., Wu, C.J., Peggs, K.S., Chan, T.A., Hadrup, S.R., Quezada, S.A., Swanton, C., Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:6280 (2016), 1463–1469.
59. [59] Calles, A., Liao, X., Sholl, L.M., Rodig, S.J., Freeman, G.J., Butaney, M., Lydon, C., Dahlberg, S.E., Hodi, F.S., Oxnard, G.R., Jackman, D.M., Janne, P.A., Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-Mutant lung cancer. J. Thorac. Oncol. 10:12 (2015), 1726–1735.
60. [60] Dudley, J.C., Lin, M.T., Le, D.T., Eshleman, J.R., Microsatellite instability as a biomarker for PD-1 blockade. Clin. Cancer Res. 22:4 (2016), 813–820.
61. [61] Joshi, N.S., Akama-Garren, E.H., Lu, Y., Lee, D.Y., Chang, G.P., Li, A., DuPage, M., Tammela, T., Kerper, N.R., Farago, A.F., Robbins, R., Crowley, D.M., Bronson, R.T., Jacks, T., Regulatory t cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43:3 (2015), 579–590.
62. [62] Keenan, B.P., Saenger, Y., Kafrouni, M.I., Leubner, A., Lauer, P., Maitra, A., Rucki, A.A., Gunderson, A.J., Coussens, L.M., Brockstedt, D.G., Dubensky, T.W. Jr., Hassan, R., Armstrong, T.D., Jaffee, E.M., A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 146:7 (2014), 1784–1794 e6.
63. [63] Beatty, G.L., Winograd, R., Evans, R.A., Long, K.B., Luque, S.L., Lee, J.W., Clendenin, C., Gladney, W.L., Knoblock, D.M., Guirnalda, P.D., Vonderheide, R.H., Exclusion of t cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4/80(+) extratumoral macrophages. Gastroenterology 149:1 (2015), 201–210.
64. [64] Wang, Q.J., Yu, Z., Griffith, K., Hanada, K., Restifo, N.P., Yang, J.C., Identification of T-cell receptors targeting KRAS-Mutated human tumors. Cancer Immunol. Res. 4:3 (2016), 204–214.
65. [65] Tran, E., Ahmadzadeh, M., Lu, Y.C., Gros, A., Turcotte, S., Robbins, P.F., Gartner, J.J., Zheng, Z., Li, Y.F., Ray, S., Wunderlich, J.R., Somerville, R.P., Rosenberg, S.A., Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350:6266 (2015), 1387–1390.
66. [66] Rosenthal, A., Mesa, R.A., Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Expert Opin. Pharmacother. 15:9 (2014), 1265–1276.
67. [67] Hurwitz, H.I., Uppal, N., Wagner, S.A., Bendell, J.C., Beck, J.T., Wade, S.M., Nemunaitis, J.J., Stella, P.J., Pipas, J.M., Wainberg, Z.A., Manges, R., Garrett, W.M., Hunter, D.S., Clark, J., Leopold, L., Sandor, V., Levy, R.S., Randomized double-blind phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastastic pancreatic cancer for whom therapy with gemcitabine has failed. J. Clin. Oncol., 2015, 10.1200/JCO.2015.61.4578.
68. [68] Pardanani, A., Laborde, R.R., Lasho, T.L., Finke, C., Begna, K., Al-Kali, A., Hogan, W.J., Litzow, M.R., Leontovich, A., Kowalski, M., Tefferi, A., Safety and efficacy of CYT387 a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 27:6 (2013), 1322–1327.
69. [69] Zhu, Z., Aref, A.R., Cohoon, T.J., Barbie, T.U., Imamura, Y., Yang, S., Moody, S.E., Shen, R.R., Schinzel, A.C., Thai, T.C., Reibel, J.B., Tamayo, P., Godfrey, J.T., Qian, Z.R., Page, A.N., Maciag, K., Chan, E.M., Silkworth, W., Labowsky, M.T., Rozhansky, L., Mesirov, J.P., Gillanders, W.E., Ogino, S., Hacohen, N., Gaudet, S., Eck, M.J., Engelman, J.A., Corcoran, R.B., Wong, K.K., Hahn, W.C., Barbie, D.A., Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 4:4 (2014), 452–465.
70. [70] Zhu, Z., Golay, H.G., Barbie, D.A., Targeting pathways downstream of KRAS in lung adenocarcinoma. Pharmacogenomics 15:11 (2014), 1507–1518.
71. [71] Kim, J.Y., Welsh, E.A., Oguz, U., Fang, B., Bai, Y., Kinose, F., Bronk, C., Remsing Rix, L.L., Beg, A.A., Rix, U., Eschrich, S.A., Koomen, J.M., Haura, E.B., Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc. Natl. Acad. Sci. U. S. A. 110:30 (2013), 12414–12419.
72. [72] Lee, H.J., Zhuang, G., Cao, Y., Du, P., Kim, H.J., Settleman, J., Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26:2 (2014), 207–221.
73. [73] Collins, M.A., Yan, W., Sebolt-Leopold, J.S., Pasca di Magliano, M., MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice. Gastroenterology 146:3 (2014), 822–834 e7.
74. [74] Ebert, P.J., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S.E., Maecker, H., Irving, B.A., Kim, J.M., Belvin, M., Mellman, I., MAP kinase inhibition promotes t cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44:3 (2016), 609–621.
75. [75] Liu, L., Mayes, P.A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., Yang, J., Seestaller-Wehr, L., Zhang, S.Y., Hopson, C., Tsvetkov, L., Jing, J., Zhang, S., Smothers, J., Hoos, A., The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin. Cancer Res. 21:7 (2015), 1639–1651.
76. [76] Ranger, G.S., Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors. Anticancer Res. 34:11 (2014), 6277–6282.